PT - JOURNAL ARTICLE AU - Otero, Sebastian AU - Miller, Emily S. AU - Sunderraj, Ashwin AU - Shanes, Elisheva D. AU - Sakowicz, Allison AU - Goldstein, Jeffery A. AU - Mithal, Leena B. TI - Maternal Antibody Response and Transplacental Transfer Following SARS-CoV-2 Infection or Vaccination in Pregnancy AID - 10.1101/2022.03.17.22272574 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.17.22272574 4099 - http://medrxiv.org/content/early/2022/03/20/2022.03.17.22272574.short 4100 - http://medrxiv.org/content/early/2022/03/20/2022.03.17.22272574.full AB - Background Pregnant persons are at increased risk of severe COVID-19 and adverse obstetric outcomes. Understanding maternal antibody response and transplacental transfer after SARS-CoV-2 infection and COVID-19 vaccination is important to inform public health recommendations.Methods This prospective observational cohort study included 351 birthing individuals who had SARS-CoV-2 infection or COVID-19 vaccination during pregnancy. IgG and IgM to SARS-CoV-2 S1 receptor binding domain were measured in maternal and cord blood. Antibody levels and transplacental transfer ratios were compared across 1) disease severity for those with SARS-CoV-2 infection and 2) infection versus vaccination.Findings There were 252 individuals with SARS-CoV-2 infection and 99 who received COVID-19 vaccination during pregnancy. Birthing people with more severe SARS-CoV-2 infection category had higher maternal and cord blood IgG levels (p=0.0001, p=0.0001). Median IgG transfer ratio was 0.87-1.2. Maternal and cord blood IgG were higher after vaccination than infection (p=0.001, p=0.001). Transfer ratio was higher after 90 days in the vaccinated group (p<0.001). Modeling showed higher amplitude and half-life of maternal IgG following vaccination (p<0.0001). There were no significant differences by fetal sex.Interpretation COVID-19 vaccination in pregnancy leads to higher and longer lasting maternal IgG levels, higher cord blood IgG, and higher transfer ratio after 90 days compared to SARS-CoV-2 infection. Greater infection severity leads to higher maternal and cord blood antibodies. Maternal IgG decreases over time following both vaccination and infection, reinforcing the importance of vaccination, even after infection, and vaccine boosters for pregnant patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from Friends of Prentice (to JAG) and the Stanley Manne Childrens Research Institute (to LBM). Investigators are supported by National Institute of Allergy and Infectious Diseases at National Institutes of Health [grant number K23 AI139337 to LBM]; and National Institute of Biomedical Imaging and Bioengineering at National Institutes of Health [grant number K08 EB030120 to JAG]. The project benefited from institutional resources supported by the National Center for Advancing Translational Sciences [UL1TR001422].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Northwestern University gave ethical approval for this work (reference number STU00212232).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.